Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19364501 | 1.00 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM3ALKBH5 | |
| SCHEMBL707808 | 1.00 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM3ALKBH5 | |
| SCHEMBL16766368 | 1.00 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM3ALKBH5 | |
| SCHEMBL29691892 | 1.00 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM3ALKBH5 | |
| Hydrochloric Acid SCHEMBL1633577 | 0.98 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM3ALKBH5 | |
| SCHEMBL12902953 | 0.93 | KMT2A (0.51) | CHRM2CHRM4CHRM5CHRM3SIGMAR1 | |
| SCHEMBL15425873 | 0.93 | KMT2A (0.51) | CHRM2CHRM4CHRM5CHRM3SIGMAR1 | |
| SCHEMBL911191 | 0.93 | KMT2A (0.51) | CHRM2CHRM4CHRM5CHRM3SIGMAR1 | |
| SCHEMBL6153627 | 0.92 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM3ALKBH5 | |
| Hydrochloric Acid SCHEMBL18063 | 0.91 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739066-B2 | Method for fluoroalkylation of enamines | ARXADA AG (CH) | 2023-08-29 | — | — | US | disclosed |
| US-11739066-B2 | Method for fluoroalkylation of enamines | ARXADA AG (CH) | 2023-08-29 | — | — | US | disclosed |
| US-20220204464-A1 | Method for Fluoroalkylation of Enamines | LONZA LTD (CH) | 2022-06-30 | — | — | US | disclosed |
| WO-2020249759-A1 | METHOD FOR FLUOROALKYLATION OF ENAMINES | LONZA LTD (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-7939527-B2 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-10 | — | — | US | disclosed |
| EP-2268646-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2009126806-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | WO | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
| US-20090062331-A1 | DEUTERIUM-ENRICHED MARAVIROC | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062331-A1 | DEUTERIUM-ENRICHED MARAVIROC | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | CHRM2 3987/4885CHRM4 3932/4885CHRM5 3886/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | CHRM2 3998/4885CHRM4 4016/4885CHRM5 3831/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | CHRM2 3837/4885CHRM4 4245/4885CHRM5 3357/4885 |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | CHRM2 2977/4885CHRM4 836/4885CHRM5 3141/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | CHRM2 3837/4885CHRM4 4245/4885CHRM5 3357/4885 |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | CHRM2 1915/4885CHRM4 795/4885CHRM5 2325/4885 |
| US-11739066-B2 | Method for fluoroalkylation of enamines | HNMT, PNMT, INMT | CHRM2 1456/4885CHRM4 836/4885CHRM5 517/4885 |
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | CHRM2 94/4885CHRM4 239/4885CHRM5 180/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | CHRM2 3998/4885CHRM4 4016/4885CHRM5 3831/4885 |
| US-20220204464-A1 | Method for Fluoroalkylation of Enamines | HNMT, PNMT, INMT | CHRM2 1456/4885CHRM4 836/4885CHRM5 517/4885 |
| US-20090062331-A1 | DEUTERIUM-ENRICHED MARAVIROC | SAMHD1, HDHD5, HSD17B3 | CHRM2 4229/4885CHRM4 3801/4885CHRM5 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.